These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 16555686)

  • 1. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
    Kecskeméti V
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
    J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
    Vieweg WV; Wood MA
    Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A; Agarwal V; Pierce WJ
    Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
    Singh M; Arora R; Jawad E
    Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
    Khan IA; Gowda RM
    Int J Cardiol; 2004 May; 95(1):1-6. PubMed ID: 15159030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.